Sequential versus Standard Triple Therapy for First-Line Helicobacter pylori Eradication: An Update.

ABSTRACT:

Background

non-bismuth sequential therapy (SEQ) was suggested as a first-line anti-Helicobacter pylori treatment alternative to standard triple therapy (STT).

Methods

We conducted a systematic review with a meta-analysis of randomized controlled trials (RCTs) comparing the efficacy of 10-day SEQ vs. STT (of at least 7 days) using bibliographical searches up to July 2021, including treatment-naïve adult or children. The intention-to-treat (ITT) eradication rate and the risk difference (RD) were calculated.

Results

Overall, 69 RCTs were evaluated, including 19,657 patients (9486 in SEQ; 10,171 in STT). Overall, SEQ was significantly more effective than STT (82% vs. 75%; RD 0.08; p < 0.001). The results were highly heterogeneous (I² = 68%)

SUBMITTER: Nyssen OP 

PROVIDER: S-EPMC10885881 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature